Cite
94% of patients suing Merck over rofecoxib agree to terms of company's offer.
MLA
Charatan, Fred. “94% of Patients Suing Merck over Rofecoxib Agree to Terms of Company’s Offer.” BMJ: British Medical Journal (International Edition), vol. 336, no. 7644, Mar. 2008, pp. 580–81. EBSCOhost, https://doi.org/10.1136/bmj.39513.541296.DB.
APA
Charatan, F. (2008). 94% of patients suing Merck over rofecoxib agree to terms of company’s offer. BMJ: British Medical Journal (International Edition), 336(7644), 580–581. https://doi.org/10.1136/bmj.39513.541296.DB
Chicago
Charatan, Fred. 2008. “94% of Patients Suing Merck over Rofecoxib Agree to Terms of Company’s Offer.” BMJ: British Medical Journal (International Edition) 336 (7644): 580–81. doi:10.1136/bmj.39513.541296.DB.